This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
40 mg subcutaneous injection (40 mg/mL) 3 times a week for the treatment of relapsing forms of multiple sclerosis.
New indications
Ibrutinib Imbruvica (Pharmacyclics) Accelerated approval for treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Previously approved for treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Not approved to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) in combination with standard antiplatelet therapy
Complete response letter: more information required
SABER-Bupivacaine
Posidur (DURECT Corp.)
Surgical site administration for postsurgical analgesia; more clinical trials will be required to assess the drug's safety.
Recommended for approval by an FDA advisory panel

Ragweed pollen allergen extract tablet
Ragwitek (Merck)
Sublingual tablet for immunotherapy for the diagnosis of ragweed polleninduced allergic rhinitis, with or without conjunctivitis recommended for approval by the FDA's Allergenic Products Advisory Committee (6-2-1).
Recommended for NON-approval by an FDA advisory panel
The FDA's Cardiovascular and Renal Advisory Committee recommended against approval of cangrelor for prevention of thrombotic events associated with coronary stenting (2-7) and for use of the drug in patients whose existing antiplatelet therapy is interrupted for surgery (0-9).
Nonsteroidal antiinfl ammatory drugs (various) The FDA's Arthritis Advisory and Drug Safety and Risk Management Advisory Committee did not agree (16-9) with the data provided the Committee to support the claim that naproxen had a lower risk of heart attacks and stroke than similar nonsteroidal anti-infl ammatory drugs.
(continued) Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. WARNINGS Constant monitoring with an electrocardiograph is essential to the proper administration of lidocaine hydrochloride intravenously. It is mandatory to have emergency resuscitative equipment and drugs immediately available to manage adverse reactions involving cardiovascular, respiratory, or central nervous systems. Anaphylactic reactions may occur following administration of lidocaine hydrochloride. In the case of severe reaction, discontinue the use of the drug. PRECAUTIONS General Caution should be employed in the repeated use of lidocaine hydrochloride in patients with severe liver or renal disease because accumulation may occur and lead to toxic phenomena, since lidocaine hydrochloride is metabolized mainly in the liver and excreted by the kidneys. The drug should also be used with caution in patients with hypovolemia and shock and in all forms of heart block. In patients with sinus bradycardia or incomplete heart block, the administration of lidocaine hydrochloride intravenously for the elimination of ventricular ectopic beats without prior acceleration in heart rate (eg, by isoproterenol or by electric pacing) may promote more frequent and serious ventricular arrhythmias or complete heart block. Most potent anesthetic agents, local anesthetics of the amide type that includes lidocaine, and muscle relaxants of both depolarizing and nondepolarizing types have been associated with malignant hyperthermia. Care should be taken in the administration of intravenous fl uids in patients with compromised myocardial function to avoid fl uid overload or disturbances of serum electrolyte concentrations which might interfere with cardiac conduction or result in congestive heart failure. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. If administration is not controlled by a pumping device, refrain from applying excessive pressure (>300 mm Hg) causing distortion to the container such as wringing or twisting. Such handling could result in breakage of the container.
(continued) WARNINGS AND PRECAUTIONS Visual fi eld defects have been reported in patients receiving topiramate independent of elevated intraocular pressure. In clinical trials, most of these events were reversible after topiramate discontinuation. If visual problems occur at any time during topiramate treatment, consideration should be given to discontinuing the drug. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm195797.htm a Practitioners are encouraged to check the FDA's MedWatch Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
